Caris Life Sciences, Inc. CAI
Sales up 97.0%, free cash flow up to $66.9M
XBRL, from each 10-KThe latest figures
Price and key numbers
All key numbers (37, from the latest 10-K and 10-Q)
- EPS (ttm)
- 1.66
- Sales (ttm)
- 1.0B
- Net income (ttm)
- 96.1M
- Sales growth
- +97.0%
- EPS growth
- -
- Sales Q/Q
- +27.0%
- Free cash flow
- 28.9M
- Gross margin
- -
- Oper. margin
- 13.4%
- Net margin
- 9.2%
- FCF margin
- 2.8%
- ROE
- 15.0%
- ROA
- 7.7%
- R&D / sales
- 12.5%
- Dividend
- -
- Debt/Eq
- 0.61
- Curr. ratio
- 6.71
- Cash
- 796.3M
- Op. cash flow (ttm)
- 83.9M
- EBITDA
- 67.7M
- EBITDA margin
- 8.3%
- Net debt
- -403.3M
- Quick ratio
- 6.71
- Interest cover
- 0.79
- FCF after stock pay
- -3.1M
- Debt / FCF (years)
- 5.87
- Goodwill / assets
- 1.7%
- Stock pay / sales
- 8.6%
- Shares out.
- 286.8M
- Shares Y/Y
- -5.8%
- Book / share
- 2.23
- Cash / share
- 2.78
- Sales / share
- 3.65
- Asset turnover
- 0.83
- Days sales out.
- 50
- Employees
- 1,846
- Sales / employee
- 568K
Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.
Revenue and net income, FY2023 to FY2025
Each fiscal year from its own 10-K · XBRL
From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2023 to FY2025 (2 years).
What the balance sheet holds, per share
Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used
Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.
CAI against Health care peers
Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.
| Company | Revenue (ttm) | Sales growthFY | Gross marginttm | Net marginttm | ROEttm | FCF marginttm | Debt / equitylatest |
|---|---|---|---|---|---|---|---|
| CAI Caris Life Sciences, Inc. | $1.0B | +97.0% | - | 9.2% | 15.0% | 2.8% | 0.61 |
| CORT Corcept Therapeutics Inc | $963.6M | +12.8% | - | 16.8% | 19.5% | 20.2% | - |
| BCRX Biocryst Pharmaceuticals Inc | $961.5M | +94.1% | 97.8% | -37.4% | - | 38.0% | - |
| IONS Ionis Pharmaceuticals Inc | $960.1M | +33.8% | - | -56.9% | -138.8% | -64.2% | 4.60 |
| BBIO BridgeBio Pharma, Inc. | $945.5M | +126% | 94.3% | -62.6% | - | -39.1% | - |
| WRBY Warby Parker Inc. | $934.7M | +13.0% | 54.7% | 0.8% | 1.9% | 2.3% | - |
Where the $812.0M of revenue came from
by product, year to Dec 31, 2025
- Molecular profiling services $766.7M · 94%
- Pharma research and development services $45.3M · 6%
From the segment tables in the 10-K XBRL.
Where the return on equity comes from
DuPont: net margin × asset turnover × leverage, FY2025 · 10-K XBRL, year-end balances
The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.
Profitability
-
Net margin above the peer median9.2% vs 6.8%
-
Return on equity above 15%15.0%
-
A profit in 0 of 3 years
Balance sheet
-
Interest covered less than 5 timesOperating income is 0.8× interest expense
-
Debt smaller than equityDebt / equity 0.61 on the latest balance sheet (peer median 0.69)
-
Current assets cover current liabilitiesCurrent ratio 6.71
-
More cash than debtNet cash $405.6M
Cash and shareholders
-
Free cash flow positive in 1 of 3 years$66.9M last year
-
Share count down over 2 years−4.3%
Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.
$400.0M of principal due, schedule of Mar 31, 2026
Debt
From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.
Contracted revenue and deferred revenue
Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL
Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.
Income statement, balance sheet and cash flow
Statements · XBRL, each 10-K and 10-Q
CAI's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 3. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.
Revenue by product or service
year to Dec 31, 2025| Revenue | Share | vs year before | |
|---|---|---|---|
| Molecular profiling services | 766.7M | 94.4% | +120% |
| Pharma research and development services | 45.3M | 5.6% | -28.2% |
10-K 0002019410-26-000016, segment and revenue notes (XBRL).
Revenue by region
year to Dec 31, 2025| Revenue | Share | vs year before | |
|---|---|---|---|
| United States | 801.4M | 98.7% | +99.4% |
| International | 10.6M | 1.3% | +2.1% |
10-K 0002019410-26-000016, segment and revenue notes (XBRL).
Income statement
From EDGAR| FY2023 | FY2024 | FY2025 | |
|---|---|---|---|
| Revenue | 306.1M | 412.3M | 812.0M |
| R&D | 116.9M | 113.9M | 101.6M |
| SG&A | 149.1M | 169.4M | 225.0M |
| Operating income | -319.6M | -257.1M | 45.1M |
| Interest expense | 31.6M | 50.0M | 56.9M |
| Pretax income | -341.4M | -281.9M | -68.1M |
| Income tax | 0 | 0 | 0 |
| Net income | -341.4M | -281.9M | -68.1M |
| EPS (diluted) | -13.24 | -10.66 | -3.22 |
| Diluted shares | 34.9M | 35.5M | 167.2M |
| Depreciation & amortization | 49.0M | 48.9M | 22.6M |
| EBITDA | -270.6M | -208.2M | 67.7M |
| Operating margin | -104.4% | -62.4% | 5.6% |
| Net margin | -111.5% | -68.4% | -8.4% |
| Revenue growth | - | +34.7% | +97.0% |
Balance sheet
From EDGAR| FY2023 | FY2024 | FY2025 | |
|---|---|---|---|
| Cash | - | 64.0M | 796.3M |
| Short-term investments | - | 2.2M | 2.3M |
| Receivables | - | 88.2M | 112.1M |
| Current assets | - | 215.7M | 997.8M |
| Property & equipment | - | 67.8M | 63.2M |
| Goodwill | - | 19.3M | 19.3M |
| Total assets | - | 343.7M | 1.1B |
| Accounts payable | - | 27.8M | 39.2M |
| Current liabilities | - | 165.4M | 127.1M |
| Total debt | - | 373.1M | 378.4M |
| Total liabilities | - | 620.9M | 548.4M |
| Shareholders' equity | -2.1B | -2.5B | 577.3M |
| Retained earnings | - | -2.5B | -2.5B |
Cash flow
From EDGAR| FY2023 | FY2024 | FY2025 | |
|---|---|---|---|
| Operating cash flow | -276.1M | -245.2M | 83.2M |
| Capital spending | 22.3M | 8.4M | 16.3M |
| Free cash flow | -298.4M | -253.6M | 66.9M |
| Stock-based pay (added back) | 15.2M | 18.6M | 70.0M |
| Free cash flow after stock pay | -313.7M | -272.3M | -3.1M |
| Buybacks | 0 | 0 | 113K |
| Investing cash flow | 214.8M | 52.9M | -16.3M |
| Financing cash flow | 10.1M | 200.3M | 665.0M |
Stock-based pay and leases
From EDGARFrom SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.
Sources
Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.
Also
Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CAI/export.csv") into a cell.